Sulfonamides & Trimethoprim: Starving Bacteria of Folate
Bacteria have to build their own folate from scratch; we simply eat ours. That single difference is a perfect weakness to exploit — and two drugs that block the folate pathway at two different steps combine into one of the most elegant antibiotics we have. But the same drug that saves lives in immunocompromised patients can also peel the skin off in a rare, terrifying reaction.
A patient with a weakened immune system is protected from a dangerous lung infection (Pneumocystis pneumonia) by a daily tablet of cotrimoxazole — a combination of a sulfonamide and trimethoprim. It works so well because the two drugs block the same essential pathway at two separate steps, choking off the folate the microbe needs to build its DNA. It's a small masterpiece of drug design. But this same combination can, rarely, unleash one of the most feared reactions in medicine — a clue that even elegant drugs demand respect.
Two blocks on one pathway
Bacteria must synthesize folate; we get it from food. Folate is essential for making the building blocks of DNA. Human cells absorb ready-made folate from the diet, but bacteria have to manufacture it themselves — and that manufacturing line is the target. Sulfonamides (like sulfamethoxazole) block the first enzyme of the pathway, and trimethoprim blocks a later one. Given alone, each merely slows bacteria; given together as cotrimoxazole, they block the SAME pathway at two consecutive points — a 'sequential blockade' that is synergistic and bactericidal, far harder for bacteria to escape. Because the enzymes they hit either don't exist in us or are shaped differently, the drugs are relatively selective for the microbe.
Where cotrimoxazole shines
Cotrimoxazole is a versatile drug. It treats urinary infections, community MRSA skin infections, and certain gut infections, but it has two standout roles in immunocompromised patients: preventing and treating Pneumocystis pneumonia (a life-threatening lung infection in HIV and other immune-suppressed people), and treating toxoplasmosis. That protective, prophylactic use in vulnerable patients is one of its most important jobs — a cheap daily pill that quietly prevents a deadly infection.
The sulfa dangers
Sulfonamides are a classic cause of drug allergy, and most reactions are a simple rash — but rarely they trigger the devastating Stevens–Johnson syndrome / toxic epidermal necrolysis, in which the skin blisters and sloughs off like a burn. They can also cause haemolysis in people with G6PD deficiency (from the metabolism chapter), and, because they displace bilirubin, they're avoided near term and in newborns for fear of kernicterus. Trimethoprim adds its own quirks: it blocks a sodium channel in the kidney much like the diuretic amiloride, so it can raise blood potassium, and because it interferes with folate it can cause a megaloblastic anaemia (given with folinic acid in high-dose or prolonged use). The pair also raise the levels of warfarin and methotrexate. Powerful and cheap — but with a real list of hazards to keep in view.
- Sulfonamides + trimethoprim block folate synthesis at two steps → sequential synergy (cotrimoxazole).
- Selective because bacteria make folate while we get it from food.
- Key uses: UTI, community MRSA, and Pneumocystis pneumonia prophylaxis/treatment in immunocompromised.
- Sulfa allergy → rash, rarely Stevens–Johnson/TEN; haemolysis in G6PD; avoid near term.
- Trimethoprim raises potassium (amiloride-like) and can cause megaloblastic anaemia.
This pair is a web of cross-connections to earlier chapters. The G6PD haemolysis is the metabolism/enzyme-deficiency lesson; the kernicterus risk echoes ceftriaxone's bilirubin displacement; trimethoprim's potassium rise mirrors the potassium-sparing diuretic amiloride from cardiology; and its folate interference is the same reason methotrexate (a human folate-pathway inhibitor) is toxic. Seeing sulfamethoxazole-trimethoprim as a node connecting metabolism, cardiology, and haematology is exactly the integrated thinking that makes a drug's dangers predictable rather than memorized.
- Continuing the drug when a spreading rash/blistering appears — could be Stevens–Johnson; stop immediately.
- Giving it to a G6PD-deficient patient or a near-term neonate — haemolysis / kernicterus.
- Ignoring the potassium rise, especially with other potassium-raising drugs.
- Forgetting it raises warfarin and methotrexate levels.
Why is the folate pathway a good antibiotic target?
- Sulfonamides + trimethoprim block folate synthesis at two steps → synergistic (cotrimoxazole).
- Selective because bacteria make their own folate; treats UTI, MRSA, Pneumocystis, toxoplasmosis.
- Sulfa allergy (rash → Stevens–Johnson), G6PD haemolysis, kernicterus risk near term.
- Trimethoprim raises potassium (amiloride-like) and can cause megaloblastic anaemia.
- Katzung BG. Basic & Clinical Pharmacology — Sulfonamides, Trimethoprim & Quinolones.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Sulfonamides & trimethoprim.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Antifolate drugs.
- Murray PR, et al. Medical Microbiology — Folate synthesis inhibitors.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Folate antagonists.
